ALK and non-small cell lung carcinoma: Based on the positive results of IMpower 150 and other phaseI/II trials, this sensitive mutation (EGFR/ALK) NSCLC will always conduct immunotherapy (monotherapy or combined with chemotherapy) after failure from first-/second-line targeted therapy.